Pathways to drug development for autism spectrum disorders

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 189-200

  Hampson, D R ^a   Gholizadeh, S ^a   Pacey, L K K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CELL PROTEIN; GUANOSINE TRIPHOSPHATASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; REELIN; VIRUS VECTOR;

A2BP1 GENE; ARTICLE; AUTISM; CLINICAL FEATURE; DRUG DEVELOPMENT; GENE; GENE THERAPY; GLIA; HUMAN; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1 GENE; NEUROLIGIN 3 GENE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAS HOMOLOG GENE FAMILY MEMBER C GENE; SHANK3 GENE; SLC25A12 GENE; SYNAPSE; TUBEROUS SCLEROSIS PROTEIN 1 GENE; TUBEROUS SCLEROSIS PROTEIN 2 GENE;

CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DRUG DISCOVERY; FRAGILE X SYNDROME; GENE THERAPY; HUMANS; MODELS, NEUROLOGICAL; RETT SYNDROME; SIGNAL TRANSDUCTION;

EID: 84855931231     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.245     Document Type: Article

References (75)

1. Huffman, L.C., Sutcliffe, T.L., Tanner, I.S. & Feldman, H.M. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J. Dev. Behav. Pediatr. 32, 56-68 (2011).
2. Nazeer, A. Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatr. Clin. North Am. 58, 85-97, x (2011).
3. Schumann, C.M. & Nordahl, C.W. Bridging the gap between MRI and postmortem research in autism. Brain Res. 1380, 175-186 (2011).
4. Anagnostou, E. & Taylor, M.J. Review of neuroimaging in autism spectrum disorders: what have we learned and where we go from here. Mol. Autism 2, 4 (2011).
5. Pierce, K. & Courchesne, E. Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. Biol. Psychiatry 49, 655-664 (2001). (Pubitemid 32328116)
6. Courchesne, E. Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Curr. Opin. Neurobiol. 7, 269-278 (1997). (Pubitemid 27219864)
7. Greco, C.M. et al. Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol. Autism 2, 2 (2011).
8. Reith, R.M., Way, S., McKenna, J. 3rd, Haines, K. & Gambello, M.J. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol. Dis. 43, 113-122 (2011).
9. Martin, L.A., Goldowitz, D. & Mittleman, G. Repetitive behavior and increased activity in mice with Purkinje cell loss: a model for understanding the role of cerebellar pathology in autism. Eur. J. Neurosci. 31, 544-555 (2010).
10. Noriuchi, M. et al. Altered white matter fractional anisotropy and social impairment in children with autism spectrum disorder. Brain Res. 1362, 141-149 (2010).
11. Voineagu, I. et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474, 380-384 (2011).
12. Penzes, P., Cahill, M.E., Jones, K.A., VanLeeuwen, J.E. & Woolfrey, K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 14, 285-293 (2011).
13. Durand, C.M. et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol. Psychiatry (in press, doi: 10.1038/mp.2011.57).
14. Bangash, M.A. et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 145, 758-772 (2011).
15. Hutsler, J.J. & Zhang, H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 1309, 83-94 (2010).
16. Tropea, D. et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U.S.A. 106, 2029-2034 (2009).
17. Darnell, J.C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011).
18. Bear, M.F., Huber, K.M. & Warren, S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004). (Pubitemid 38829251)
19. Hampson, D.R., Adusei, D.C. & Pacey, L.K. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Biochem. Pharmacol. 81, 1078-1086 (2011).
20. Jacquemont, S. et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra1 (2011).
21. Levenga, J., de Vrij, F.M., Oostra, B.A. & Willemsen, R. Potential therapeutic interventions for fragile X syndrome. Trends Mol. Med. 16, 516-527 (2010).
22. Hagerman, R., Hoem, G. & Hagerman, P. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol. Autism 1, 12 (2010).
23. Chez, M.G., Burton, Q., Dowling, T., Chang, M., Khanna, P. & Kramer, C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J. Child Neurol. 22, 574-579 (2007). (Pubitemid 46951501)
24. Fatemi, S.H., Reutiman, T.J., Folsom, T.D. & Thuras, P.D. GABA(A) receptor downregulation in brains of subjects with autism. J. Autism Dev. Disord. 39, 223-230 (2009).
25. Oblak, A.L., Gibbs, T.T. & Blatt, G.J. Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J. Neurochem. 114, 1414-1423 (2010).
26. Yip, J., Soghomonian, J.J. & Blatt, G.J. Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. Autism Res. 2, 50-59 (2009).
27. Harada, M. et al. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J. Autism Dev. Disord. 41, 447-454 (2011).
28. Chao, H.T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-269 (2010).
29. Pacey, L.K., Doss, L., Cifelli, C., van der Kooy, D., Heximer, S.P. & Hampson, D.R. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol. Cell. Neurosci. 46, 563-572 (2011).
30. Pacey, L.K., Heximer, S.P. & Hampson, D.R. Increased GABA(B) receptormediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 76, 18-24 (2009).
31. Atladóttir, H.O. et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 124, 687-694 (2009).
32. Ronald, A. & Hoekstra, R.A. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 255-274 (2011).
33. Betancur, C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 1380, 42-77 (2011).
34. Miles, J.H. Autism spectrum disorders-a genetics review. Genet. Med. 13, 278-294 (2011).
35. Pinto, D. et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466, 368-372 (2010).
36. Abrahams, B.S. & Geschwind, D.H. Connecting genes to brain in the autism spectrum disorders. Arch. Neurol. 67, 395-399 (2010).
37. Levy, D. et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 70, 886-897 (2011).
38. Garbett, K. et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 30, 303-311 (2008).
39. Boda, B., Dubos, A. & Muller, D. Signaling mechanisms regulating synapse formation and function in mental retardation. Curr. Opin. Neurobiol. 20, 519-527 (2010).
40. Sosunov, A.A. et al. Tuberous sclerosis: a primary pathology of astrocytes? Epilepsia 49 (suppl. 2), 53-62 (2008). (Pubitemid 351143766)
41. Ehninger, D. & Silva, A.J. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol. Med. 17, 78-87 (2011).
42. Gross, C. et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30, 10624-10638 (2010).
43. Sharma, A. et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694-702 (2010).
44. Ricciardi, S. et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 20, 1182-1196 (2011).
45. Weng, N., Weiler, I.J., Sumis, A., Berry-Kravis, E. & Greenough, W.T. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1253-1257 (2008).
46. Osterweil, E.K., Krueger, D.D., Reinhold, K. & Bear, M.F. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616-15627 (2010).
47. Sokol, D.K., Maloney, B., Long, J.M., Ray, B. & Lahiri, D.K. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76, 1344-1352 (2011).
48. Westmark, C.J. & Malter, J.S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52 (2007).
49. Lee, E.K. et al. hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat. Struct. Mol. Biol. 17, 732-739 (2010).
50. Ashwood, P., Nguyen, D.V., Hessl, D., Hagerman, R.J. & Tassone, F. Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav. Immun. 24, 898-902 (2010).
51. Vargas, D.L., Nascimbene, C., Krishnan, C., Zimmerman, A.W. & Pardo, C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57, 67-81 (2005). (Pubitemid 40053317)
52. Goines, P. & Van de Water, J. The immune system's role in the biology of autism. Curr. Opin. Neurol. 23, 111-117 (2010).
53. Giulivi, C. et al. Mitochondrial dysfunction in autism. JAMA 304, 2389-2396 (2010).
54. Parker-Athill, E.C. & Tan, J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals. 18, 113-128 (2010).
55. Wei, H. et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J. Neuroinflammation 8, 52 (2011).
56. Singer, H.S., Morris, C.M., Gause, C.D., Gillin, P.K., Crawford, S. & Zimmerman, A.W. Antibodies against fetal brain in sera of mothers with autistic children. J. Neuroimmunol. 194, 165-172 (2008).
57. Wills, S. et al. Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism. Mol. Autism 2, 5 (2011).
58. Patterson, P.H. Maternal infection and immune involvement in autism. Trends Mol. Med. 17, 389-394 (2011).
59. Bhat, R. & Steinman, L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64, 123-132 (2009).
60. Boulanger, L.M. Immune proteins in brain development and synaptic plasticity. Neuron 64, 93-109 (2009).
61. Careaga, M., Van de Water, J. & Ashwood, P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 7, 283-292 (2010).
62. Morgan, J.T. et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol. Psychiatry 68, 368-376 (2010).
63. Maezawa, I. & Jin, L.W. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci. 30, 5346-5356 (2010).
64. Jacobs, S. & Doering, L.C. Astrocytes prevent abnormal neuronal development in the fragile x mouse. J. Neurosci. 30, 4508-4514 (2010).
65. Yuskaitis, C.J., Beurel, E. & Jope, R.S. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim. Biophys. Acta 1802, 1006-1012 (2010).
66. Graeber, M.B. Changing face of microglia. Science 330, 783-788 (2010).
67. Dong, Y. & Benveniste, E.N. Immune function of astrocytes. Glia 36, 180-190 (2001). (Pubitemid 33055906)
68. Paribello, C. et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91 (2010).
69. Lee, M., McGeer, E.G. & McGeer, P.L. Mechanisms of GABA release from human astrocytes. Glia 59, 1600-1611 (2011).
70. D'Hulst, C. et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 1253, 176-183 (2009).
71. Snyder, B.R., Boulis, N.M. & Federici, T. Viral vector-mediated gene transfer for CNS disease. Expert Opin. Biol. Ther. 10, 381-394 (2010).
72. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M. & Kaspar, B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65 (2009).
73. Haberman, R.P. & McCown, T.J. Regulation of gene expression in adeno-associated virus vectors in the brain. Methods 28, 219-226 (2002). (Pubitemid 35341085)
74. Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007). (Pubitemid 46328028)
75. Zeier, Z., Kumar, A., Bodhinathan, K., Feller, J.A., Foster, T.C. & Bloom, D.C. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther. 16, 1122-1129 (2009).